Residency · Residency · Psychiatry
Stimulant Use Disorders: Cocaine and Methamphetamine
Epidemiology
Cocaine use disorder: ~1.4 million Americans (2022 NSDUH) Methamphetamine use disorder: ~1.6 million Americans; rapidly increasing, especially in western and rural US. Stimulant overdose deaths rising steeply, especially combined with fentanyl ("speedballing" with opioids) Methamphetamine is now the most commonly used stimulant worldwide. Higher prevalence in men, MSM populations, and individuals experiencing homelessness.
Neurobiology
| Feature | Cocaine | Methamphetamine |
|---|---|---|
| Primary mechanism | Monoamine reuptake blockade (DAT, NET, SERT) | Monoamine release + reuptake blockade |
| Half-life | ~1 hour | ~10-12 hours |
| Duration of action | 15-30 min (smoked/IV) to 60-90 min (intranasal) | 8-12+ hours |
| Neurotoxicity | Minimal at typical use | Significant (dopaminergic/serotonergic terminal damage) |
| Cardiovascular | Coronary vasospasm, Na+ channel blockade | Cardiomyopathy, pulmonary hypertension |
| Unique complications | MI in young patients; wide QRS in OD | "Meth mouth"; formication; cardiomyopathy |
| Psychosis rate | ~5-10% with chronic use | 40-50% with chronic use |
| Medical management of chest pain | Benzodiazepines + NTG; AVOID beta-blockers | Supportive; benzodiazepines |
Cocaine
Blocks reuptake of dopamine, norepinephrine, and serotonin by binding to monoamine transporters (DAT, NET, SERT) Primary mechanism of reinforcement: DAT blockade in the nucleus accumbens. Also blocks voltage-gated sodium channels (local anesthetic and cardiotoxic properties) Routes of administration affect onset and addiction liability: smoked (crack) and IV > intranasal > oral. Short half-life (~1 hour) leads to rapid cycling of intoxication and crash.
Methamphetamine
Promotes RELEASE of monoamines (dopamine, norepinephrine, serotonin) from presynaptic terminals, in addition to blocking reuptake. More potent and longer-lasting than cocaine (half-life ~10-12 hours) Neurotoxic: causes dopaminergic and serotonergic terminal damage, oxidative stress, and microglial activation. Structural brain changes: reduced gray matter in prefrontal cortex, striatum; some recovery with prolonged abstinence. Smoked (crystal meth) is the most common form; also used IV, intranasal, oral.
Neuroadaptation
Chronic stimulant use leads to dopamine depletion in the nucleus accumbens and prefrontal cortex. Post-acute withdrawal: anhedonia, fatigue, hypersomnia, dysphoria, cognitive impairment, intense craving. Prefrontal cortex dysfunction impairs decision-making and impulse control.
Clinical Presentation
Stimulant Intoxication
Euphoria, increased energy, decreased need for sleep, hyperalertness. Sympathomimetic signs: tachycardia, hypertension, mydriasis, hyperthermia, diaphoresis. Psychomotor agitation, grandiosity, impaired judgment. Severe: chest pain, arrhythmias, seizures, stroke, myocardial infarction. Cocaine-specific: coronary vasospasm (even in young patients without atherosclerosis) Methamphetamine-specific: dental destruction ("meth mouth"), skin excoriations from formication (tactile hallucinations of insects under skin)
Stimulant Withdrawal
Not medically dangerous (unlike alcohol/benzodiazepine withdrawal) but profoundly dysphoric. "Crash" phase: hypersomnia, increased appetite, psychomotor retardation, depressed mood. Protracted withdrawal: anhedonia, fatigue, craving -- may persist for weeks to months. No specific pharmacotherapy for stimulant withdrawal; supportive care.
Stimulant-Induced Psychosis
Occurs in up to 40-50% of chronic methamphetamine users. Paranoid delusions, auditory and visual hallucinations, ideas of reference. Can be indistinguishable from primary psychotic disorders (paranoid schizophrenia) Usually resolves within days to weeks of abstinence, but may persist in a minority of patients. Risk factors: higher dose, longer duration, route (smoked/IV), sleep deprivation, genetic vulnerability. Treatment: antipsychotics (atypical preferred); benzodiazepines for acute agitation. Sensitization: repeated stimulant exposure lowers the threshold for psychosis (similar to kindling)
Pharmacotherapy -- The Gap
No FDA-Approved Pharmacotherapies
This is the central challenge in stimulant use disorder treatment. Dozens of agents have been studied with disappointing results.
Agents Under Investigation
Topiramate: some positive RCTs for cocaine use disorder; reduces glutamate and enhances GABA; side effects limit tolerability. Bupropion + naltrexone combination: theoretical rationale (dopamine enhancement + reward modulation); some positive trials for methamphetamine use disorder. Mirtazapine: some evidence for methamphetamine use disorder in MSM populations; may reduce use. Methylphenidate/dextroamphetamine (agonist therapy): studied in analogy to methadone for OUD; mixed results for cocaine; a large Dutch trial (ADAPT) showed positive results for dextroamphetamine in chronic cocaine dependence. Modafinil: theoretical benefit via glutamate modulation; results have been mixed. N-acetylcysteine (NAC): restores glutamate homeostasis; preclinical promise; clinical trials mixed. Vaccines and monoclonal antibodies: anti-cocaine vaccine studied in trials; limited efficacy due to variable antibody response; active area of research.
Behavioral Interventions
Contingency Management (CM)
The strongest evidence-based treatment for stimulant use disorders. Operant conditioning: provides tangible reinforcers (gift cards, vouchers, prizes) contingent on objectively verified abstinence (urine drug screens) Effect sizes: large (d = 0.5-0.6), superior to all other behavioral interventions for stimulants. Prize-based CM (fishbowl method): patients draw from a bowl for prizes of varying value when they provide a negative UDS. Barriers to implementation: concern about "paying patients to not use drugs," funding, regulatory issues. VA system has implemented CM as standard of care for stimulant use disorders (2023) SAMHSA now supports CM programs.
Community Reinforcement Approach (CRA)
Behavioral therapy that restructures the patient's environment so that non-drug activities become more reinforcing than drug use. Components: functional analysis, social/recreational counseling, job skills, relationship counseling. Often combined with CM (CRA + vouchers) -- the most effective behavioral combination.
Cognitive Behavioral Therapy
Relapse prevention model: identifying high-risk situations, developing coping strategies, managing craving. Effective but smaller effect sizes than CM for stimulant use disorders specifically. Matrix Model: structured 16-week outpatient program combining CBT, family education, 12-step facilitation, and contingency management; originally developed for methamphetamine use disorder.
12-Step Programs
Cocaine Anonymous, Crystal Meth Anonymous. Peer support, structured framework. Limited controlled evidence but widely available and valued by many patients.
Medical Complications
Cardiovascular (Cocaine)
Coronary vasospasm and acute MI (even in young patients) Aortic dissection. Arrhythmias (sodium channel blockade -- widened QRS) Management of cocaine chest pain: benzodiazepines, nitroglycerin, aspirin; AVOID beta-blockers (unopposed alpha stimulation can worsen coronary vasospasm) Phentolamine for refractory hypertension.
Cardiovascular (Methamphetamine)
Dilated cardiomyopathy (methamphetamine-associated cardiomyopathy; may be partially reversible with abstinence) Pulmonary hypertension. Arrhythmias.
Neurological
Hemorrhagic and ischemic stroke. Seizures. Movement disorders (choreoathetosis with chronic use)
Infectious
HIV, HCV (especially with IV use) Endocarditis. Skin and soft tissue infections.
<image> A comparison diagram of cocaine versus methamphetamine pharmacology. Two columns. For each: mechanism of action at the dopamine transporter (blockade vs. release), half-life, neurotoxicity, cardiovascular effects, psychosis risk, dental effects, and route-of-administration effects on addiction liability. Include a simplified diagram of the dopamine synapse showing where each drug acts. Neuroscience education style. </image>
<image> A pyramid diagram showing the evidence hierarchy for stimulant use disorder treatments. At the top (strongest evidence): contingency management. Below: CBT/relapse prevention, community reinforcement approach, Matrix Model. At the bottom (weakest/experimental): pharmacotherapies (topiramate, bupropion + naltrexone, mirtazapine, agonist replacement). Include effect sizes where available. Note the absence of FDA-approved pharmacotherapies. Clinical education format. </image>
<image> An infographic on stimulant-induced psychosis. Show: prevalence in chronic methamphetamine users (40-50%), common symptoms (paranoid delusions, auditory/visual hallucinations, formication, ideas of reference), differentiating features from primary psychotic disorders (acute onset with stimulant use, resolution with abstinence within days-weeks, but may persist), risk factors (dose, duration, route, sleep deprivation, genetic vulnerability), and treatment approach (atypical antipsychotics, benzodiazepines, abstinence). Include the concept of sensitization. Clinical education style. </image>
Clinical Pearls
There are NO FDA-approved pharmacotherapies for stimulant use disorders -- contingency management is the most effective treatment and should be offered whenever possible. Stimulant-induced psychosis can be indistinguishable from schizophrenia on cross-sectional assessment -- longitudinal observation during abstinence is essential for accurate diagnosis. In cocaine-associated chest pain, NEVER give beta-blockers -- they cause unopposed alpha-adrenergic stimulation worsening hypertension and vasospasm; use benzodiazepines and nitroglycerin instead. Methamphetamine is neurotoxic and causes a cardiomyopathy that may be partially reversible with sustained abstinence -- this is a powerful motivational tool for patients. The "crash" after stimulant cessation is not medically dangerous but features intense dysphoria and hypersomnia -- patients need support but not specific pharmacotherapy. Contingency management works through positive reinforcement, not bribery -- it is the only intervention with large effect sizes for stimulant abstinence and is now standard of care at the VA.
References
- De Crescenzo F, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction. PLoS Med. 2018;15(12):e1002715.
- Tardelli VS, et al. Pharmacological interventions for methamphetamine use disorder: a systematic review and network meta-analysis. Addiction. 2023;118(5):811-826.
- Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care. 2011;38(1):41-58.
- Trivedi MH, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140-153.
- Rawson RA, et al. A comparison of contingency management and cognitive-behavioral approaches during treatment for methamphetamine dependence. Arch Gen Psychiatry. 2006;63(11):1270-1276.
